All News
Tendon Inflammation May Signal Early RA
Tenosynovitis may represent a preclinical phase of rheumatoid arthritis (RA).
Read ArticleGastrointestinal Perforation Risk increased for Tofacitinib and Tocilizumab
Gastrointestinal perforations (GIP) are not historically believed to be a common or uncommon complication. Hence, when this was noted in the tocilizumab (TCZ) and tofacitinib (TOFA) developmental trials, it was a curious if not perplexing finding.
Read ArticlePatients Undertreated and Uninformed on Pain Meds and NSAIDs
Pain management in the U.S. is at a vexing crossroad. The news tells us that narcotics are increasingly being restricted for their dangerous side effects and inappropriate use.
Read ArticleArhalofenate, URAT-1 Inhibitor, Being Developed for Gout
Good news for gout patients includes the recent approval of Zurampic (lesinurad), a URAT-1 inhibitor, and that effective urate-lowering therapy has significant long-term cardiovascular benefits.
Read ArticleRheumNow Week in Review – 27 May 2016
Dr. Cush reviews highlights from this week on RheumNow.com.
Read Article
Mosquito Arthritis
In the last two years there have been increasing reports of mosquito-borne infectious arthritides. Dengue fever was best known until the introduction of viral infections due to chikungunya and Zika.
Read ArticleIL-23 Inhibitor Effective in Crohn's Disease
Selective IL-23 inhibition has been touted to be the next great advance in the treatment of inflammatory bowel and psoriatic disease.
Read ArticleTocilizumab Effective in PMR
Polymyalgia rheumatica (PMR) should be easy and responsive, but it can be a challenge and requires long-term steroid therapy. Problems often begin when steroid–induced side effects take their toll on a patient, especially in elderly adults.
Read ArticleOpioid Prescriptions in Decline
In an era of increasing fears over narcotic abuse and narcotic-related deaths, the number of opioid prescriptions in the United States is finally falling, the according to the NY Times.
Read ArticleTB Management Questions
The following is a compilation of several frequently asked questions regarding tuberculosis (TB) testing or treatment in patients on a TNF inhibitor (TNFi) or other biologic agents.
Read ArticleORBIT Study Shows Rituximab and TNF inhibitor Equivalence
The initial choice of biologic is crucial to long-term success. Yet there are few studies evaluating head-to-head differences in some of our most popular therapies.
Read ArticleRheumNow Week in Review - 19 May 2016
Dr. Jack Cush reviews this week's news and research highlights from RheumNow.com.
Read ArticleFDA Delays Ruling on Generic Labeling
The New York Times reports that the FDA has delayed its much anticipated ruling on generics until sometime in 2017.
Read ArticleMusculoskeletal Complications of Hematologic Disorders Reviewed
Morais and colleagues have published an informative review of rheumatologic and musculoskeletal (MSK) disorders that may potentially befall those with benign or malignant blood disorders. It is important to be aware of these associations.
Read ArticleGWAS Reveals Shared Susceptibility Locus Between RA and SLE
While the phenotypes of RA and SLE are quite different, genome-wide association studies (GWAS) performed in the past have shown a genetic overlap between both.
Read ArticleRisk Factors for Bisphosphonate Bone Complications
Rare reports of bisphosphonate associated atypical femoral fractures (AFF) and osteonecrosis of the jaw (ONJ) have raised concerns about the chronic use of bisphosphonates. The risk of AFF and ONJ was assessed in an analysis of the Swedish national database.
Read ArticleReports Call for More Gout Education
Two recent surveys show that gout patients are often uninformed, undertreated, improperly monitored and frequently stigmatized by their gout.
Read ArticleCochrane Reports Moderate Evidence Favoring Biologic Add-on Therapy
Singh and coworkers have assessed the value of adding a biologic to rheumatoid arthritis (RA) patients not responding to either methotrexate (MTX) or DMARDs. The results of their netowork metanalsysis is published as a Cochrane review wherein they examined a total of 90 RCTs (73 new) with 32
Read ArticleNetrin-1 May Promote Lung Fibrosis in Scleroderma
Mechanisms underlying the pulmonary fibrosis of systemic sclerosis are poorly understood, yet are the focus of both research and new drug development.
Read ArticleRheumNow Week in Review – 13 May 2016
Dr. Cush reviews highlights from this week on RheumNow.com.
Read Article